Forced degradation studies of new formulation containing naltrexone

Forced degradation studies of new formulation containing naltrexone

Naltrexone is one of the classical opioid antagonists. In substantially lower than standard doses, they apply different pharmacodynamics. A daily dose of 1 to 5 mg is considered as low-dose naltrexone (LDN). Clinical reports of LDN have demonstrated its possible benefits in diseases such as fibromyalgia, Crohn’s disease, multiple sclerosis, complex-regional pain syndrome, Hailey-Hailey disease, and cancer.

___

  • Alsante M, Ando A, Brown R, Ensing J, Hatajik TD, Kong W, Tsuda Y (2007). The role of degradant profiling in active pharmaceutical ingredients and drug products. Adv Drug Deliv Rev 59(1): 29-37.
  • Brown SA, D’Amico EJ, McCarthy DM, Tapert SF (2001). Four year outcomes from adolescent alcohol and drug treatment. J Stud Alcohol 62: 381–388.
  • Klick S, Muijselaar PG, Waterval JCM, Eichinger T, Korn C, Gerding KT, Debets AJ, Griend CS, Beld C, Somsen GW, De Jong GJ (2005). Toward a generic approach for : Stress testing of drug substances and drug products. Pharm Technol 29(2): 48-66.
  • Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O’Brien CP (2016). Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med 374(13): 1232–1242.
  • Modesto-Lowe V, Van Kirk J (2002). Clinical uses of naltrexone: A review of the evidence. Exp Clin Psychopharmacol 10(3): 213-227.
  • Volkow ND, Li TK (2004). Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci 5(12): 963-970.